Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel F Carr

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Frontiers in Pharmacology|July 20, 2023
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene studyLaurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
British Journal of Clinical Pharmacology|March 8, 2014
Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatmentTjeerd P van Staa, Daniel F Carr, Helen O'Meara, et al.
Frontiers in Pharmacology|September 18, 2023
Corrigendum: <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene studyLaurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
Pharmacogenetics and Genomics|February 26, 2015
HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysisElena M Cornejo Castro, Daniel F Carr, Andrea L Jorgensen, et al.
Clinical Pharmacology and Therapeutics|December 17, 2025
Improving Genotype Imputation in High-Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning ApproachesInnocent G Asiimwe, Tao You, Daniel F Carr, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohortDaniel F Carr, Charles J L la Porte, Munir Pirmohamed, et al.
Pharmacogenomics|June 11, 2013
Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UKAna Alfirevic, Daniel F Carr, Fabio Miyajima, et al.
British Journal of Clinical Pharmacology|December 7, 2013
Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research DatalinkHelen O'Meara, Daniel F Carr, Jane Evely, et al.
Pharmacogenomics|December 19, 2024
Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic reviewLisanne A H Bevers, Rebecca L Jensen, Andrew Owen, et al.
Pharmacogenetics and Genomics|December 14, 2007
Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicityDaniel F Carr, Ana Alfirevic, Jonathan D Tugwood, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Frontiers in Pharmacology|July 20, 2023
<i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene studyLaurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
British Journal of Clinical Pharmacology|March 8, 2014
Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatmentTjeerd P van Staa, Daniel F Carr, Helen O'Meara, et al.
Frontiers in Pharmacology|September 18, 2023
Corrigendum: <i>CYP3A</i> genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene studyLaurence McEvoy, Joanne Cliff, Daniel F Carr, et al.
Pharmacogenetics and Genomics|February 26, 2015
HLA-allelotype associations with nevirapine-induced hypersensitivity reactions and hepatotoxicity: a systematic review of the literature and meta-analysisElena M Cornejo Castro, Daniel F Carr, Andrea L Jorgensen, et al.
Clinical Pharmacology and Therapeutics|December 17, 2025
Improving Genotype Imputation in High-Dimensional Pharmacogenomics Using Multiple Imputation: Evaluation with Machine Learning ApproachesInnocent G Asiimwe, Tao You, Daniel F Carr, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2010
Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohortDaniel F Carr, Charles J L la Porte, Munir Pirmohamed, et al.
Pharmacogenomics|June 11, 2013
Institutional profile: the Wolfson Centre for Personalised Medicine, University of Liverpool, Liverpool, UKAna Alfirevic, Daniel F Carr, Fabio Miyajima, et al.
British Journal of Clinical Pharmacology|December 7, 2013
Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the Clinical Practice Research DatalinkHelen O'Meara, Daniel F Carr, Jane Evely, et al.
Pharmacogenomics|December 19, 2024
Genetic variation on dolutegravir pharmacokinetics and relation to safety and efficacy outcomes: a systematic reviewLisanne A H Bevers, Rebecca L Jensen, Andrew Owen, et al.
Pharmacogenetics and Genomics|December 14, 2007
Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicityDaniel F Carr, Ana Alfirevic, Jonathan D Tugwood, et al.
Pageof 5